UK shareholder meetings calendar - next 7 days
23rd Jun 2026 12:42
4basebio PLC - Cambridge, England-based life sciences company - Appoints mRNA biology and translation specialist Jeff Coller to its Strategic Advisory Board. Coller's expertise will assist with the company's efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics. Read More
Tullow Oil PLC - London-based oil and gas company - Director Garrett Soden buys 426,000 shares at 15.2 pence each on Friday. Worth total GBP64,752. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
4basebio PLC - Cambridge, England-based life sciences company - Appoints Richard Bungay as chief financial officer. Bungay will assume the role from July 2026, succeeding David Roth. Bungay previously served as chief executive officer and chief financial officer of Diurnal Group PLC, the Cardiff, Wales-based pharma company, and he currently serves as a non-executive director of Chroma Therapeutics Ltd, the Birmingham, England-based biotechnology company. Amy Walker, 4basebio chief executive officer, says: "Richard has a long and accomplished career in the industry... we are thrilled that he has decided to join 4basebio." Read More
4basebio PLC - Cambridge, England-based life sciences company - Launches high-capacity single stranded-DNA for therapeutics. The company says the platform, ssDNA, will "accelerate the development of safer, more precise genetic therapies by targeting gene editing, advanced cell engineering and innovative nucleic acid-based medicines." 4basebio will showcase its proprietary advancements at the American Society for Gene & Cell Therapy Annual Meeting in Boston on May 14, 2026. Read More
(Alliance News) - 4Basebio PLC on Tuesday said it is expanding to a new innovation hub and manufacturing facility at its headquarters in Cambridge, England to support growing demand. Read More
4basebio PLC - Cambridge, England-based life sciences company - Appoints Scott Lorimer as chief operating officer, with immediate effect. This follows the appointment last week of Christine Wolosin as chief commercial officer, and of Amy Walker last month as chief executive. 4basebio says he will be responsible for scaling its synthetic DNA platform to serve its client base in the cell and gene therapy, mRNA, and vaccine markets. He will also oversee manufacturing operations, quality and regulatory compliance, process development, and supply chain and facility management. Read More
(Alliance News) - 4basebio PLC on Tuesday announced the promotion of Business Development Vice President Christine Wolosin to chief commercial officer, following the appointment of Amy Walker to chief executive last month. Read More
(Alliance News) - 4basebio PLC on Tuesday said it has promoted Chief Operating Officer Amy Walker to chief executive officer, succeeding founder Heikki Lanckriet. Read More
(Alliance News) - 4basebio PLC on Monday said its synthetic DNA product has been used in US clinical trials by a "global tier one" pharmaceutical partner. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - 4basebio on Tuesday reported a wider pretax loss in 2024, despite higher revenue, and said it is optimistic about the year to come. Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Secures good manufacturing practice, or GMP, certification for its UK DNA manufacturing facility from the UK Medicines & Healthcare Products Regulatory Agency. This authorises it to manufacture and supply investigational medicinal product drug substance and critical starting biological medicinal materials used in advanced therapy medicinal products from its Cambridge facility, says the firm. Adds that the certification strengthens its position in the advanced therapeutics field and progresses it towards commercialisation and patient care for a range of advanced therapies. Chief Executive Heikki Lanckriet says: "Achieving GMP certification is a critical milestone for 4basebio, validates our ability to supply synthetic DNA for clinical applications and underscores the hard work and innovation of our team and sets the stage for the next phase of growth for the company." Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Names Gabe Longoria as the new chief commercial officer. Longoria was previously CCO at Astrea Bioseparations Ltd. The appointment follows a GBP40 million investment into 4basebio by Elevate Medical Technologies and M&G Investment Management Ltd, which completed in November. This is a "key milestone" for the company. Read More
4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio. Read More
(Alliance News) - 4basebio PLC on Thursday noted a "key milestone" with its client, which is progressing into a phase one clinical trial. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
4basebio PLC - Cambridge, England-based life-science tech company with proprietary technologies in the field of DNA synthesis - Announces success in tender process to supply research and GMP-grade synthetic DNA for the development of RNA therapeutics and vaccines at the CPI's RNA Centre of Excellence. The CPI is a UK government-supported organisation which offers development and scale-up services to companies. The Centre for Excellence is the name for its Darlington manufacturing facility. Read More